Get better Answers
With Innovative, Adaptive Clinical Trials.
Berry Consultants ("Berry") is a scientific consulting company specializing in innovative adaptive clinical trial design, analysis, implementation, and software solutions for the pharmaceutical and medical device industry.
To seek efficient answers for new medical advancements, you need more. That’s why Berry offers innovative statisticians and software for the freedom to design and implement adaptive clinical trials. Get the answers you need from analysis to approval and beyond.
Innovative Trials, Better Outcomes.
Berry has extensive experience in the design, implementation, and software solutions of adaptive clinical trials across many medical disciplines. Adaptive trials can result in better insights, greater efficiency, better treatment for subject in a trial, and better information for regulators and the medical community. Here’s the Adaptive Trial Process.
Adaptive Clinical Trial Design
Allow the pre-specification of flexible components to the major aspects of a trial, like the treatment arms, the allocation to the different treatment arms, the patient population, and the sample size.
Trial Implementation
Our services include interim and final analyses for primary and key secondary efficacy endpoints, providing expert guidance on best practices for adaptive design implementation, and interacting with Data Safety Monitoring Boards (DSMB) for adaptive and platform trials.
Clinical Trial Software
Software solutions that help Biostatisticians rapidly design, compare, and simulate both fixed and adaptive trial designs through powerful, versatile and fast simulation tools.
Platform Trials
Innovative clinical trials that evaluate multiple treatments simultaneously and intended to continue beyond the evaluation of any one treatment, while maximizing statistical and clinical efficiency.
Latest News and Events
Episode 18, “A Statistician Reads JAMA"
Dr. Scott Berry applies a statistician’s review of a random trial result published in JAMA – the FAIR-HF2 clinical trial. Interrogating the frequentist paradigm and the focus on the binary outcome of the primary hypothesis test.
FACTS 7.2 Release
Berry Consultants is excited to announce the release of version 7.2 of FACTS (Fixed and Adaptive Clinical Trial Simulator) today, which now includes a broader set of dose escalation designs.
Episode 17, “Seamless 2/3 Trial Designs"
Scott Berry convenes co-authors Kert Viele, Joe Marion, and Lindsay Berry to discuss the statistical and developmental nuances of inferentially seamless phase 2/3 clinical trial designs.
Episode 16, “Spending Alpha"
In this solo episode of "In the Interim...", Scott Berry, President and Senior Statistical Scientist at Berry Consultants, addresses deep-rooted confusion in the field of adaptive clinical trial design surrounding the concept of “spending alpha.”
Latest Publications
We’re continually refining and reshaping the clinical trials for the betterment of our clients and their patients.
